Losartan (potassium)

• UNSPSC Description:

  Losartan potassium (DuP-753 potassium) is an angiotensin II receptor type 1 (AT1) antagonist, competing with the binding of angiotensin II to AT1 with an IC50 of 20 nM.

• Target Antigen:

  Angiotensin Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cardiovascular Disease; Endocrinology; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Losartan-potassium.html

• Solubility:

  DMSO : ≥ 110 mg/mL|H2O : 50 mg/mL (ultrasonic)

• Smiles:

  OCC1=C(Cl)N=C(CCCC)N1CC2=CC=C(C3=CC=CC=C3C4=N[N-]N=N4)C=C2.[K+]

• Molecular Weight:

  461.00

• References & Citations:

  [1]Burnier, M. Angiotensin II type 1 receptor blockers. Circulation, 2001. 103(6): p. 904-12.|[2]Ashry, O., et al. Evidence for expression and function of angiotensin II receptor type 1 in pulmonary epithelial cells. Respir Physiol Neurobiol, 2014.|[3]Choi, C.H., et al. Angiotensin II type I receptor and miR-155 in endometrial cancers: synergistic antiproliferative effects of anti-miR-155 and losartan on endometrial cancer cells. Gynecol Oncol, 2012. 126(1): p. 124-31.|[4]Habashi, J.P., et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science, 2006. 312(5770): p. 117-21.|[5]Campbell, D.J., et al. Effects of losartan on angiotensin and bradykinin peptides and angiotensin-converting enzyme. J Cardiovasc Pharmacol, 1995. 26(2): p. 233-40.Cell Death Dis. 2020 May 22;11(5):390.|Chem Biol Interact. 2023 Jul 14;110636.|FASEB J. 2019 May;33(5):6254-6268. |Am J Physiol Heart Circ Physiol. 2018 Mar 1;314(3):H580-H592.|Am J Physiol Renal Physiol. 2020 Nov 1;319(5):F941-F953.|Antioxidants (Basel). 2024 Aug 7;13(8):958.|Apoptosis. 2024 Jun 9.|Arch Biol Sci. 2021 Jun.|Biomolecules. 2022, 12(12), 1754.|Biomolecules. 2023 Apr 25, 13(5), 740.|Clin Sci. 2021 Mar 26;135(6):793-810.|Clin Transl Med. 2023 Mar;13(3):e1213.|FASEB J. 2018 Sep;32(9):5051-5062.|Friedrich-Alexander University Erlangen-Nuremberg. 2023 May 2.|Front Physiol. 2020 Sep 8;11:560170.|Gene. 2022 Jan 31;146239.|Int Immunopharmacol. 2023 Aug 4;123:110761.|Int Immunopharmacol. 2024 Jul 19:139:112707.|Int J Mol Sci. 2023 Feb 3;24(3):2960.|Int J Nanomedicine. 2018 Nov 13;13:7409-7426. |J Immunother Cancer. 2024 Sep 6;12(9):e009327.|J Orthop Surg Res. 2024 Feb 19;19(1):147.|J Pharmacol Sci. 2020 Sep;144(1):30-42.|J Physiol. 2023 Dec 28.|J Transl Med. 2024 Jan 5;22(1):26.|Nefrologia. 2023 Sep 6.|Oncogene. 2023 Feb 23.|Oxid Med Cell Longev. 2022 Feb 18;2022:5044046.|Phytomedicine. 2022 Mar 21;100:154067.|Phytomedicine. 2023 Feb 4;112:154700.|Rep Biochem Mol Biol. 2021 Jul;10(2):314-326.|Reports of Biochemistry and Molecular Biology. 2021 Aug.|Res Sq. 2024 Jul 16.|Research Square Print. September 13th, 2022.|Sci Rep. 2019 Dec 19;9(1):19450.|Toxicol Appl Pharmacol. 2024 Apr 28:486:116945.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  Launched

• CAS Number:

  124750-99-8